Sep 21, 2015
Washington Healthcare Update
This Week: President Obama Nominates Food and Drug Administration (FDA)
Deputy Commissioner Robert Califf to Head the Agency… Congressional Budget
Office (CBO) Estimate Says Eliminating the Affordable Care Act’s (ACA)
Individual Mandate Would Reduce Budget Deficit by $305 Billion by 2025…
Montana Submits Formal Medicaid Expansion Waiver to Centers for Medicare and
Medicaid Services (CMS)
House of Representatives
District Work Period: Sept. 21–Sept. 25
3. State Activities
4. Regulations Open for Comment
District Work Period: Sept. 21–Sept. 25
House Ways and Means Committee Marks Up and Approves Seven Health, Tax-Related Bills; Approves Two Small Affordable Care Act (ACA) Adjustments
The House Ways and Means Committee held a hearing Sept. 17 to mark up seven bills, two of which are related to health care. The two bills, approved and
reported out of the committee, were:
H.R. 2061, Equitable Access to Care and Health “EACH Act”
: Sponsored by Rep. Rodney Davis (R-IL), the bipartisan bill would expand the religious liberty exemption to the individual mandate in the ACA. Sen.
Kelly Ayotte (R-NH) has introduced an identical Senate version with 30 cosponsors.
H.R. 1270, “Restoring Access to Medication Act of 2015”
: Sponsored by Rep. Lynn Jenkins (R-KS), the bill would allow people to use their health savings accounts (HSAs), flexible spending accounts (FSAs) and
other similar accounts to buy over-the-counter medications. Sen. Pat Roberts (R-KS) introduced a Senate version of the bill, also with bipartisan
For more information or to view the hearing, visit waysandmeans.house.gov.
House Energy and Commerce Health Subcommittee Holds Hearing on Medicaid Legislation
The House Energy and Commerce Subcommittee on Health held a hearing Sept. 18 entitled “Improving the Medicaid Program for Beneficiaries” to hear testimony
from disease groups and researchers on four legislative proposals to update programs within Medicaid. The subcommittee last week discussed six additional
Medicaid bills in its ongoing effort to strengthen Medicaid.
The bills discussed at the hearing include:
Michael Boyle, M.D.
Vice President of Therapeutics Development
The Cystic Fibrosis Foundation
Senior Vice President for Health Services
Special Needs Alliance
For more information or to view the hearing, visit energycommerce.gov.
Conservative Republican Study Committee Releases Their Desired Budget
On Sept. 15, Chair of the Republican Study Committee Bill Flores (R-TX) offered his caucus’s government funding proposal,
the Responsible Spending and Accountability Act (RSAA) of 2015
, which is similar to the budget passed by the House and Senate. The RSAA would adopt the FY 2016 appropriations package, including the six appropriation
bills passed by the House earlier this year. It would also include several conservative policy priorities, including measures to defund all abortion
providers, ban the sale of fetal tissues, defund the Affordable Care Act (ACA) and limit executive authority over immigration amnesty and the Iran nuclear
In addition to 12 appropriations bills, the RSAA includes more than 180 amendments adopted on the House floor from 107 Members of Congress, which include
bolstering funding for national security, decreasing bureaucratic authority at the Internal Revenue Service (IRS) and the Environmental Protection Agency
(EPA), and reduce taxes and restrictions on businesses and investors. The plan intends to pressure on Republican leadership, who is trying to prevent a
government shutdown over Planned Parenthood funding.
Bipartisan Cadillac Tax Repeal Legislation Introduced in the Senate
On Sept. 18 Sens. Dean Heller (R-NV) and Martin Heinrich (D-NM) introduced a bill
to repeal the Affordable Care Act’s (ACA) Cadillac tax. The Cadillac tax is a 40 percent excise tax on high-cost health insurance plans that begins in
2018. The tax was designed to put downward pressure on health costs and payroll taxation. The tax applies to family health care coverage exceeding $27,500
and individual coverage exceeding $10,200, with low inflation adjustments intended to capture more taxpayers over time. The biggest obstacle to the bill,
aside from President Obama’s veto, is the cost of repealing the tax. The Congressional Budget Office (CBO) projects the tax will generate $87 billion for
the government over the next decade. The bill is a Senate companion to U.S. Congressman Joe Courtney’s (D-CT) House legislation. There are two bills in the
House of Representatives on this issue, which combined have 288 cosponsors.
A joint press release on the legislation can be found here.
Senate Judiciary Antitrust Subcommittee to Hold Hearing on Consumer Impact of Health Insurance Industry Consolidation
The Senate Committee on Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights has scheduled a hearing entitled “Examining
Consolidation in the Health Insurance Industry and its Impact on Consumers” on Tuesday, Sept. 22, 2015, at 10 a.m., in Room 226 of the Dirksen Senate
Office Building. Members will question witnesses on the consumer impacts of the proposed insurance industry mergers of Anthem and Cigna and of United and
Humana that were announced earlier this year. The impending mergers involving these four major providers have raised concerns about antitrust issues as
well as patient choice.
Mr. Mark T. Bertolini
Chairman and Chief Executive Officer
Mr. Joseph R. Swedish
President and Chief Executive Officer
Dr. Paul Ginsburg
Norman Topping Chair in Medicine and Public Policy
University of Southern California
Dr. Leemore S. Dafny
Kellogg School of Management, Northwestern University
Mr. Richard J. Pollack
President and Chief Executive Officer
American Hospitals Association
Mr. George Slover
Senior Policy Counsel
For more information or to view the hearing, visit
Senate Health, Education, Labor and Pensions (HELP) Subcommittee Holds Hearing on the Food and Drug Administration’s (FDA) Progress on Biosimilars
The Senate HELP Subcommittee on Primary Health and Retirement Security held a hearing Sept. 17 in which FDA’s Director of the Center for Drug Evaluation
and Research, Jane Woodcock, testified that should the Centers for Medicare and Medicaid Services (CMS) proceed with its proposal to put biosimilars that
reference the same brand biologic into single billing codes, the FDA would collaborate with CMS to develop a method to use some codes, or “coding
modifiers,” to track which patients received which medications.
The hearing gave committee members an opportunity to receive a status report on the progress FDA has made on implementing legislation that created a
pathway for biosimilars to be approved. Director Woodcock asked legislators for additional financial resources for educational campaigns for target
stakeholder groups around biosimilars. At the hearing, Sen. Christopher Murphy (D-CT) questioned Director Woodcock on how CMS’s biosimilar billing proposal
would affect her agency’s use of the codes for safety purposes, and Sens. Tim Scott (R-SC) and Elizabeth Warren (D-MA) probed Director Woodcock about the
agency’s delay in releasing guidance documents on biosimilar labeling and interchangeability. The FDA intends to release that guidance later this year. In
August the FDA released a naming guidance document that proposed adding non-meaningful, four-letter suffixes to the nonproprietary names of biologics and
Janet Woodcock, M.D.
Center for Drug Evaluation and Research, Food and Drug Administration
For more information or to view the hearing, visit help.senate.gov.
Senate Health, Education, Labor and Pensions (HELP) Committee Holds Hearing on Electronic Health Records; Chair Calls for Delay of Stage 3 of
Meaningful Use Rules Until 2017
Senate HELP Committee Chair Lamar Alexander (R-TN) held a hearing Sept. 16 to discuss ways to improve care through increasing patients’ accessibility to
their own health records. At the hearing, Chair Alexander called on the Department of Health and Human Services (HHS) to delay the agency’s final rule for
the third stage of meaningful use of the electronic health records program until 2017 and to phase-in the last stage of the program’s requirements based on
how successfully it is implemented. Provider groups have voiced similar concerns and have asked the agency to hold off on the changes to Stage 2 and delay
finalizing the third stage of the meaningful use program. The White House Office of Management and Budget is reviewing both the modifications to the second
stage of the program and the foundational plans for the third stage of the program. Witnesses at the hearing testified about the need to involve patients
in their own care and the challenges surrounding that task. Chair Alexander indicated that he and committee staffs are crafting a handful of legislative
changes to improve the meaningful use program.
Raj Ratwani, Ph.D.
Scientific Director, National Center for Human Factors in Healthcare, MedStar Health
Assistant Professor of Emergency Medicine, Georgetown University School of Medicine
Kathy Giusti, MBA
Founder and Executive Chairman
Multiple Myeloma Research Foundation
Intel Fellow, General Manager for Health and Life Sciences
For more information or to view the hearing, visit
Democratic, Bicameral Legislation Proposed to Allow the Government to Negotiate Prescription Drug Prices
Sen. Bernie Sanders (I-VT) and House Oversight and Government Reform Committee Ranking Member Elijah Cummings (D-MD) recently introduced legislation to
address rising prescription drug prices. The Prescription Drug Affordability Act of 2015 (S.2023 and H.R.3513)
authorizes the Secretary of the Department Health and Human Services (HHS) to negotiate drug prices with pharmaceutical companies for the Medicare program.
The bill also includes tougher penalties for drug companies that commit fraud, and bans the practice of brand-name drugmakers’ paying competitors to keep
lower-priced generic substitutes off the market. The bill also lowers barriers to the importation of lower-cost drugs from Canada. The legislation is
cosponsored by Democrats including Sen. Al Franken (MN) and Reps. Keith Ellison (MN), Eleanor Holmes Norton (D-DC) and John Sarbanes (MD). Data from the
Centers for Medicare and Medicaid Services show that drug prices rose more than 12 percent last year, a gain that is more than double the rise in overall
medical costs. The Congressional Budget Office historically has said that government negotiations for drugs in the Medicare program would not save the
A fact sheet on the bill can be found here.
A press release on the legislation can be found
Federal Judge Issues Injunction Against Centers for Medicare and Medicaid Services’ Fixed Indemnity Rule
On Sept. 11, Federal Judge Royce Lambert issued a permanent injunction in Central United Life v. Burwell that bars the Obama Administration from
enforcing a 2014 rule to restrict the sale of stand-alone “fixed indemnity” insurance plans unless they include coverage that meets the Affordable Care
Act’s (ACA) individual mandate requirements. These plans are sometimes called “skimpy plans.” In the rule, CMS allows for the continued marketing of
per-service indemnity policies, but only if certain requirements are met.
Central United Life Insurance Company, which offers fixed indemnity plans, brought the lawsuit against the Department of Health and Human Services (HHS) on
grounds that the rule violated previous federal law allowing fixed indemnity plans. Pre-ACA regulations had provided that fixed indemnity coverage had to
pay benefits on a per-period basis, for example, $100 per day of hospitalization. In the new regulation, an insurer could pay either a service-based
benefit or a time-based benefit, but, once an insured had a triggering event, such as a diagnosis of cancer, the carrier would have to pay a set benefit
and not an “excepted benefit.” CMS’s rule applies to individual hospital indemnity insurance, individual critical illness insurance and other individual
supplemental health insurance products. Companies that violated that rule would be subject to fines of up to $100 per day per customer.
Food and Drug Administration (FDA) Releases Final Rule on Drug Destruction Authority at the U.S. Border
FDA finalized without changes a final rule that implements Section 708 of the
Food and Drug Administration Safety and Innovation Act (FDASIA), which allows the agency to destroy personally imported drugs valued at or below $2,500
that have been refused at the U.S. border. The rule is designed to prevent successive attempts at importation. The rule also requires FDA to provide
written notice to owners or consignees of the drugs of the agency’s plan to destroy the drugs and gives the owner of the drugs the option to present
testimony prior to the destruction of the drugs. A group of bipartisan senators sent a letter to FDA in
June 2014 concerning the proposed regulation, arguing that it “constitutes a potential health threat to hundreds of thousands of Americans who receive
their affordable drugs from safe, licensed and legal pharmacies in Canada.” In the letter, they requested “the final regulation contain a requirement that
patients be notified that their drugs could be destroyed at least six months in advance of their medication being denied to them.” The rule becomes
effective Oct. 15, 2015.
The Food and Drug Administration (FDA) Declines Request for Special Flexibility for Orphan Drug Applications
On Sept. 17, the Food and Drug Administration declined a request from the National Organization for Rare Disorders (NORD) to officially provide “special
flexibility” as the agency undergoes its review process for applications for orphan drugs. In the decision, FDA rationalized that such a policy could imply an abdication of
safety and effectiveness standards. FDA noted that orphan drugs have been aided by a number of actions, including having official consent to perform only
one trial and having smaller clinical trial populations (sometimes with fewer than 20 participants). FDA’s action came in response to a 2011 citizen petition submitted by NORD to formalize the leniency that
regulators have historically given to orphan drugs. Studies are more difficult to conduct because, by definition, the diseases are rare and the number of
individuals available for clinical trials is smaller. The citizen petition also sought a formal acknowledgement from FDA that orphan drug clinical trials
and application reviews are “qualitatively and quantitatively different” from those encompassing standard prescription drugs.
President Obama Nominates Food and Drug Administration (FDA) Deputy Commissioner Robert Califf to Head the Agency
On Sept. 15, President Obama announced the nomination of
FDA Deputy Commissioner Robert Califf, a cardiologist and a former Duke professor, to serve as Administrator to the Food and Drug Administration. Since
February 2015, Dr. Califf has been serving as deputy commissioner for medical products and tobacco and managing FDA’s Office of Special Medical Programs.
Dr. Califf additionally served on the Institute of Medicine committees that recommended Medicare coverage of clinical trials and the removal of ephedra
from the market. In his current role, he directs FDA efforts covering precision medicine, combination products, orphan drugs, pediatric therapeutics and
the advisory committee system.
Federal Exchange CEO Sends Letter to Insurers to Reaffirm Centers for Medicare and Medicaid Services’s (CMS) Dedication to Its Out-of-Pocket Caps
The Obama Administration sent a
letter to a trade association representing larger employer employee benefit and compensation insurers, the ERISA Industry
Committee, reaffirming the Administration’s controversial change to the method for calculating 2016 out-of-pocket caps. On Nov. 26, 2014, the Department of
Health and Human Services (HHS) published a notice of proposed rulemaking to clarify that “the annual limitation on cost sharing for self-only coverage be
applied to all individuals regardless of whether the individual is covered by a self-only plan or is covered by a plan that is other than self-only.”
In the letter from Healthcare.gov CEO Kevin Counihan, he stated, “We believe that applying the individual $6,850 maximum annual limitation on cost sharing
to individuals covered by a plan that is other than self-only helps remedy the difficulty a consumer could face in paying up to $13,700 out-of-pocket for
certain covered medical care under the plan because he or she purchased family coverage instead of self-only coverage.” The new policy is meant to protect
consumers enrolled in family coverage from running up medical bills of more than $6,850 per year and the policy applies to all non-grandfathered small and
large group health plans including self-insured plans.
Bureau of Labor Statistics (BLS) Releases Data Hinting at Potential for Higher Medicare Part B Premiums in 2016 for Some Beneficiaries
BLS released data Sept. 16 that means it is likely that Social Security recipients will not receive a cost of living adjustment (COLA). Medicare
beneficiaries who pay the lowest Part B premium directly to Social Security — about 70 percent of all beneficiaries — can’t be required to pay any premium
increases at all next year. Medicare Trustees reported in July that they anticipated Medicare part B premiums to rise because of Medicare policies that
have been successful in pushing more care to the outpatient setting. By law Medicare Part B premiums from beneficiaries are to cover 25 percent of Part B’s
overall cost. Because 70 percent of Medicare beneficiaries are held harmless in instances in which there is no COLA and premiums increase, Medicare has to
collect more from a smaller pool of beneficiaries.
On Oct. 15, the Bureau of Labor Statistics will release the final data needed to officially calculate the cost-of-living adjustment; at that time, SSA will
announce a cost-of-living adjustment for 2016.
3. State Activities
Montana Submits Formal Medicaid Expansion Waiver to Centers for Medicare and Medicaid Services (CMS)
On Sept. 16, Montana submitted a
Medicaid expansion waiver
to CMS, which would require income-eligible Montanans to pay monthly premiums equal to 2 percent of household income as well as the maximum copay
permitted. The state has asked CMS to approve the waiver by Nov. 1, so coverage can start in January with health insurance exchange open enrollment. Under
the Affordable Care Act, the federal government will fund 100 percent of the expansion through 2016, which will gradually decline to 90 percent by 2020.
Montana will be the first state in the nation to use a private company to administer Medicaid expansion under the Affordable Care Act (ACA), if CMS
approves the waiver. The state legislature approved the expansion this spring, making Montana the 29th state to expand Medicaid under the ACA. The
expansion is expected to provide additional coverage to an estimated 70,000 Montanan residents who make between 100 and 138 percent of the federal poverty
line. CMS has expressed some concern over the waiver, due to its cost-sharing provisions on low-income residents. CMS will be taking public comment on the
state’s proposal through Oct. 15.
Virginia Hospitals Launches Campaign Against Falling Medicare and Medicaid Reimbursements
The Virginia Hospital and Healthcare Association has initiated a grassroots movement called “Hospitals:
Our Lifeline” to raise statewide awareness highlighting financial challenges to the industry, which include declining Medicare and Medicaid reimbursements.
The effort includes TV, digital, billboards and radio ads that will aim to highlight the impact hospitals in the state have on job growth, economic
activity and access to care.
California State Legislature Passes Legislation to Cap Copays for Medically Necessary Prescription Drugs
The California state legislature passed a bill, AB 339, on
Sept. 11 that implements a cost cap on copays and coinsurance for a single 30-day prescription at $250, or $500 for people on bronze-level plans. The
legislation, sponsored by Assemblyman Rich Gordon (D-Menlo Park), mirrors a copay prescription cost mandate put in place on the state’s exchange plans this
spring. The legislation now heads to Democratic Gov. Jerry Brown for a signature.
4. Regulations Open for Comment
The Centers for Medicare and Medicaid Services (CMS) Offers Long-term Care Reform Proposed Rule
In conjunction with the White House Conference on Aging, the Centers for Medicare and Medicaid Services released a long-term care reform proposed rule July 16. The rule concerns reducing unnecessary hospital
readmissions and infections, and strengthening safety measures for the nearly 1.5 million residents in the more than 15,000 long-term care facilities or
nursing homes that participate in the Medicare and Medicaid programs. The proposed changes include:
Ensuring nursing home staff is properly trained on caring for residents with dementia and in preventing elder abuse.
Ensuring that staff members have the right skill sets and competencies to provide person-centered care to residents.
Improving care planning, including discharge planning for all residents with involvement of the facility’s interdisciplinary team and consideration of
the caregiver’s capacity, giving residents information they need for follow-up, and ensuring that instructions are transmitted to any receiving
facilities or services.
Allowing dietitians and therapy providers the authority to write orders in their areas of expertise when a physician delegates the responsibility and
state licensing laws allow.
Updating the nursing home’s infection prevention and control program, including requiring an infection prevention and control officer and an antibiotic
Many of the proposals in the draft rule build on improvements that nursing homes have already made since 1991, the last time these conditions of
participation were comprehensively updated. The recommended reforms were published in a proposed rule in the July 16, 2015, Federal Register. The comment period for the proposed rule ended on Sept. 14, 2015, and was
reopened until Oct. 15, 2015.
Department of Health and Human Services (HHS) Proposes Updates to “the Common Rule”
HHS and 15 other agencies released a notice of proposed rulemaking Sept. 2 for the Common Rule, the
existing regulatory framework to transparency and oversight for scientific research involving human subjects. The proposed changes are to address the
substantial changes that have occurred within scientific research. Current regulations have been in place since 1991 and are followed by 18 federal
agencies. Proposed updates to the rule include:
Strengthened informed consent provisions
Requirements for administrative or IRB review that would align better with the risks of the proposed research
New data security and information protection standards
Requirements for written consent for use of an individual’s biological samples, for example, blood or urine, for research with the option to consent to
their future use for unspecified studies
Requirement, in most cases, to use a single institutional review board for multisite research studies
Application of rule to clinical trials, regardless of funding source, if they are conducted in a U.S. institution that receives funding from a Common
Rule agency for research involving human participants.
In July 2011, HHS issued an Advance Notice of Proposed Rulemaking to seek the public’s input on updating the Common Rule. The proposed rule issued reflects
input and requests comments for HHS to consider as it drafts the final rule. HHS will take public comment on the proposed rule until Dec. 7.
For a press release detailing changes to the rule visit hhs.gov.
Department of Health and Human Services (HHS) Releases Proposed Rule on Health Equity
On Sept. 3, HHS issued a proposed rule, Nondiscrimination in
Health Programs and Activities, to advance health equity and reduce disparities in health care. The proposed rule establishes that the prohibition on sex
discrimination includes discrimination based on gender identity. It also includes requirements for effective communication for individuals with
disabilities and enhanced language assistance for people with limited English proficiency. The proposed rule applies to Health Insurance Marketplaces, any
health program that HHS itself administers, and any health program or activity any part of which receives funding from HHS, such as hospitals that accept
Medicare patients or doctors who treat Medicaid patients. Finally, the proposed rule extends these nondiscrimination protections to individuals enrolled in
plans offered by issuers participating in the Health Insurance Marketplaces and explicitly bars any marketing practices or benefit designs that
discriminate on the basis of race, color, national origin, sex, age or disability. Section 1557 of the Affordable Care Act (ACA) extended civil rights
protections banning sex discrimination to health programs and activities. Previously, civil rights laws enforced by HHS’s Office for Civil Rights (OCR)
barred discrimination based only on race, color, national origin, disability or age. The rule will be published in the Federal Register on Sept. 8,
and is open for public comment through Nov. 6, 2015.
For more information, including a fact sheet and Frequently Asked Questions, visit hhs.gov.
Internal Revenue Service (IRS) Proposed Rule Mandates Employer Health Plans Offer Hospital and Physician Services
The IRS released a proposed rule Aug. 31 that would require employer health
plans to offer substantial coverage for inpatient hospital services and physician services. The Affordable Care Act requires employer health plans to be at
least 60 percent of the minimum value standard. News reports uncovered the fact that employer plans could do so without providing hospital or physician
The preamble of the proposal points out that while large group plans are not required to cover the ACA’s Essential Health Benefit, a plan that does not
cover hospital and physician services “does not meet a universally accepted minimum standards of value expected from and inherent in any arrangement that
can reasonably be called a health plan and that is intended to provide the primary health coverage for employees.”
Under the proposed rule, an employer group health plan must, to meet the minimum value standard (MSV) and avoid a penalty, meet or exceed an actuarial
value standard of at least 60 percent coverage including substantial coverage for doctor and hospital services. The proposed rule provides a transition
period for employers that have previously offered non-compliant coverage prior to Nov. 4, 2014. The proposal aligns IRS and Department of Health and Human
Services (HHS) policies. The ACA compels employers who do not meet the affordability and MSV thresholds to pay a penalty of $3,000 for each worker that
receives a tax credit. The IRS proposed rule, published in the Federal Register Sept. 1, also says that any employee offered a non-compliant plan
would not be prevented from receiving premium tax credits. IRS is taking comments on the proposed rule until Nov. 2, 2015.
Centers for Medicare and Medicaid Services (CMS) Issues FY 2016 Final Inpatient and Long-Term Care Hospital Policy and Payment Changes
CMS issued a final rule on July 31, 2015, to update fiscal year
(FY) 2016 Medicare payment policies and rates under the Inpatient Prospective Payment System (IPPS) and the Long-Term Care Hospital (LTCH) Prospective
Payment System (PPS).
For hospitals paid under the IPPS that successfully participate in the Hospital Inpatient Quality Reporting (IQR) Program and demonstrate meaningful use of
certified electronic health record technology, the increase in rates is 0.9 percent. This is calculated from a hospital market basket update of 2.4 percent
adjusted by -0.5 percent for multi-factor productivity and an additional adjustment of -0.2 percent in accordance with requirements of the Affordable Care
Act and further adjusted by - 0.8 percent for a documentation coding recoupment adjustment required by the American Taxpayer Relief Act of 2012.
Hospitals that do not successfully participate in the Hospital IQR program and do not submit the required quality data will be subject to a one-fourth
reduction of the market basket update. In addition the law required that the update for any hospital that is not a meaningful user of electronic health
records will be reduced by one-half of the market basket update in FY 2016. Other payment adjustments will include continued penalties for readmissions, a
continued -1 percent penalty for hospitals in the worst-performing quartile under the hospital acquired condition reduction program and continued bonuses
and penalties for hospital valued-based purchasing.
Medicare Disproportionate Share Hospital (DSH) payments will also change. CMS is distributing an estimated $6.4 billion in uncompensated care payments in
FY 2016, a decrease from FY 2015, which is attributable to the continued declines in the number of uninsured.
The rule contains a number of other policy changes. A fact sheet on the final rule can be found here. The final rule will be published
on Aug. 17, 2015. Comments may be made on the final rule and are due to CMS by Sept. 29, 2015, and the rule is effective Oct. 1, 2015.
Food and Drug Administration (FDA) Issues Final Rule to Phase Out Trans Fats
FDA issued a
final rule June 16
that gives the food manufacturers three years to phase out partially hydrogenated oils (PHOs), which are still used in a wide variety of food products from
microwave popcorn to cake frosting. The decision finalizes an agency determination that PHOs, the primary dietary source of artificial trans fat in
processed foods, are not “generally recognized as safe” or GRAS for use in human food. Since 2006, manufacturers have been required to include trans fat
content information on the Nutrition Facts label of foods. Between 2003 and 2012, the FDA estimates that consumer trans fat consumption decreased about 78
percent and that the labeling rule and industry reformulation of foods were key factors in informing healthier consumer choices and reducing trans fat in
foods. Comments on the final rule are due by June 18, 2018.
More information on FDA’s decision can be found in the agency’s
Government Accountability Office (GAO) Releases Report on CMS Oversight of State Health Insurance Exchange Technology Projects
GAO released a report Sept. 16 detailing inefficient CMS oversight of state health insurance exchange
technology projects. GAO studied how states have used federal funds for IT projects to support their marketplaces, delineated CMS’s and states’ roles in
overseeing these projects, and identified IT challenges states have encountered and lessons learned. States identified a number of challenges in
establishing their IT systems to support their marketplaces, including project management and oversight, system design and development, resource allocation
and distribution, and marketplace implementation and operation. States also identified lessons learned from dealing with such challenges, including the
need for strong project management and clear requirements development.
GAO found that as of March 2015, states spent about $1.45 billion in federal marketplace grant funding on information technology (IT) projects supporting
health insurance marketplaces; the majority of this spending was for state-based marketplaces. These marketplaces reported spending nearly 89 percent of
the funds on IT contracts, and CMS has ongoing efforts to track states’ IT spending in more detailed categories.
In its recommendations, GAO advised that CMS define and communicate its oversight roles and responsibilities, ensure senior executives are involved in
funding decisions for state IT projects and ensure states complete testing of their systems before they are put into operation.
The Center for American Progress (CAP) Unveils New Proposals for Addressing High Prescription Drug Costs
CAP released a report on Sept. 18
detailing a series of proposals to address the rising costs of prescription drugs. CAPs suggestions include limiting patient out-of-pocket cost sharing for
drugs by insurers, requiring companies to participate in a star ratings system of comparative effectiveness in drug labeling and marketing, and
implementing cost transparency requirements for drug manufacturers. CAP also offered the idea of authorizing objective third-party groups to evaluate
drugs’ effectiveness and offer appropriate payment ranges; should the negotiated price of drugs lie outside the third-party’s recommended pay range, then
federally funded drug patents for those drugs would be licensed to competitors.
The Congressional Budget Office (CBO) Releases Estimate on Employer Small Group Market Delay
CBO and the Joint Committee on Tax (JCT) released a preliminary cost estimate of H.R. 1624, Protecting Affordable Coverage for Employees Act, a bill that
would recognize firms with 50 or fewer employees as “small employers” unless their state decides to expand the small group market to 100 employees in 2016.
CBO and JCT expect that most states will not elect to expand the definition; therefore, most firms with between 51 and 100 employees will no longer
be subject to certain requirements established by the Affordable Care Act or be able to offer coverage through a SHOP exchange. In their analysis, CBO and
JCT estimated that the small group market delay would increase federal revenues by $400 million from 2015 to 2025. CBO and JCT estimate that H.R. 1624
would result in a net reduction in premiums for health insurance purchased by some firms with between 51 and 100 employees. Premiums would be lower, at
least in the near term, because some firms would choose to offer insurance that does not meet the standards required under current law.
Congressional Budget Office (CBO) Estimate Says Eliminating the Affordable Care Act’s (ACA) Individual Mandate Reduces Budget Deficit by $305 Billion
CBO and the Joint Committee on Tax (JCT) released a
of the budget impact of eliminating the ACA individual health insurance mandate and associated penalties and determined that eliminating that requirement
would reduce the deficit by about $305 billion between the 2015 and 2025 period. That figure, when broken down, consists of a $311 billion decrease in
direct spending, which would be partially offset by a $6 billion decrease in revenues. Most spending reductions would be due to $110 billion less in
outlays for exchange subsidies and $200 billion less for Medicaid and the Children’s Health Insurance Program, or CHIP, the report said.
The report comes with a caveat. CBO and JCT also concluded that eliminating the individual mandate would increase the number of people without health
insurance coverage in 2025 by about 14 million people, resulting in 41 million uninsured in that year. CBO and JCT also noted that the elimination of the
individual mandate would increase individual premium prices by roughly 20 percent in all years between 2017 and 2025.
Harvard Study Finds Medicare’s 30-Day Readmission Policy Penalizes
Hospitals with Sickest, Poorest Patient Populations
In a study released Sept. 14 by JAMA Internal Medicine, Harvard researchers
found that Medicare unfairly penalizes hospitals with higher than expected readmission rates by up to 3 percent of annual inpatient payments, largely based
on the characteristics of the patient populations the hospitals serve. The researchers found that nearly two dozen variables, such as patients’ income,
level of education and ability to bathe, dress and feed themselves, attributed to about 48 percent of the difference in 30-day readmission rates between
the best- and worst-performing hospitals. Patient characteristics are not included in Medicare’s current risk-adjustment methods. Researchers contend that
this could explain much of the difference in readmission risk between patients admitted to hospitals with higher versus lower readmission rates.
Department of Health and Human Services (HHS) Office of the Inspector General (OIG) Report Details Centers for Medicare and Medicaid Services
Mismanagement of Healthcare.gov Private Contractors
OIG released a detailed audit report on Sept. 15 that found that CMS’s contracting
personnel did not properly manage and oversee Healthcare.gov private contractor performance. OIG reviewed 20 of 62 contracts awarded by HHS to private
contractors in conjunction with the construction of the federal health insurance exchange website, which was inundated with technical glitches in the first
several months of the Affordable Care Act’s (ACA) exchange rollout. Because CMS did not always provide adequate contract management and oversight for
Federal marketplace contracts, contractor delays and performance issues, OIG found, were not always identified; a contractor incurred unauthorized costs
that increased the cost of the contract; contracting officers in all government agencies did not have access to contractor past-performance evaluations
when making contract awards; and critical deliverables and management decisions were not properly documented. OIG issued a number of personnel and
contracting-related recommendations to CMS, which the agency agreed to in addition to written corrective actions it had taken or planned to take to address
Hospital Trade Association Comments Urge the Centers for Medicare and Medicaid Services (CMS) to Waive Penalties for Proposed Joint Replacement Pay
Bundle Till Year Three of the Demonstration
The American Hospital Association (AHA) submitted comments to CMS on Sept. 8 asking the agency
to waive several regulations in its five-year Comprehensive Care for Joint Replacement (CCJR) payment model that CMS proposed
in July. In this model, hospitals where hip or knee replacement take place would be held accountable by CMS for the quality and cost of care from the time
of surgery through 90 days after discharge; hospitals would then be eligible to receive an additional bonus payment or be required to repay Medicare for a
portion of care costs, depending on the quality of care the hospital provides and its cost performance. AHA, which represents the long-term care hospitals
that could be negatively impacted by the proposed pilot project, generally supports the pay demo, but does not wish to see it expanded.
AHA’s comments called for additional protections for provider organizations, including waiving several key components of the demo: the physician
self-referral law, the anti-kickback statute waiver, discharge-planning requirements that disallow hospitals from influencing beneficiaries’ choice of
post-acute care providers, the requirement that patients be admitted as inpatients for three days before Medicare pays for nursing home services, and the
“60 percent rule” that determines whether inpatient rehab facilities are compensated at higher rates than hospitals. AHA also recommends delaying by six
months the demonstration start date (till July 1, 2016), postponing until the third year penalties for hospitals that don’t meet spending goals of demo
implementation, restricting enrollment in the CCJR program to voluntary hip and knee replacement episodes, and incorporating a risk-adjustment approach for
hospitals. The way CMS pays for hip and knee replacement procedures in this demo will likely be an archetype for alternative payment models that CMS plans
to use for many other procedures and conditions. The proposed CCJR start date is Jan. 1, 2016.
If you have any questions, contact the following individuals at
Kennan, Senior Vice President
Charlyn Iovino, Vice
Founded in 1998, McGuireWoods Consulting LLC (MWC) is a full-service public affairs firm offering state and federal government relations, national/multistate strategies, infrastructure and economic development, strategic communications and grassroots issue management services. McGuireWoods Consulting is a subsidiary of the
McGuireWoods LLP law firm and in 2010 was ranked in the Top 20 of The National Law Journal's "The Influence 50," an annual report of the top public affairs firms in Washington, D.C.
To sign up for the Weekly Washington Healthcare Update, use our online
McGuireWoods Consulting LLC
2001 K Street
Washington, DC 20006-1040